A microRNA CRISPR screen reveals microRNA-483-3p as an apoptotic regulator in prostate cancer cells.

ABSTRACT: The development of traditional protein-targeted cancer therapies is a slow and arduous process, often taking years or even decades. In contrast, RNA-based therapies targeting crucial microRNA (miRNA) offer a faster alternative due to the sequence-specific nature of miRNA inhibitor binding. This, combined with the capacity of individual miRNA to influence multiple cellular pathways, makes these small RNA attractive targets for cancer therapy. While miRNA are known to be dysregulated in prostate cancer (PCa), identifying their individual contributions to disease progression and the identification of therapeutically actionable miRNA targets in PCa has been challenging due to limited profiling and lack of screening tools. To address this need, we developed miRKOv2, a miRNA-only CRISPR knockout

SUBMITTER: Chow JT 

PROVIDER: S-EPMC12552650 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature